Protara Therapeutics, Inc.
TARA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001359931
In the last 90 days, Protara Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.0M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Protara Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 35
- −1 vs. Q2 2024
- Shares held
- 10.4M
- +415.9K (+4.1%) vs. Q2 2024
- Total value
- $19.1M
- −$2.25M (−10.5%) vs. Q2 2024
- New holders
- 6
- 13 more added
- Sold out
- 7
- 7 more reduced
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TARA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 119 | $176.0M |
| Q1 2026 | 114 | $237.4M |
| Q4 2025 | 105 | $212.3M |
| Q3 2025 | 81 | $114.0M |
| Q2 2025 | 76 | $90.1M |
| Q1 2025 | 59 | $123.8M |
| Q4 2024 | 60 | $156.6M |
| Q3 2024 | 35 | $19.1M |
| Q2 2024 | 38 | $22.2M |
| Q1 2024 | 34 | $18.3M |
| Q4 2023 | 30 | $8.17M |
| Q3 2023 | 31 | $8.55M |
| Q2 2023 | 29 | $12.3M |
| Q1 2023 | 29 | $16.9M |
| Q4 2022 | 30 | $14.7M |
| Q3 2022 | 31 | $16.7M |
| Q2 2022 | 33 | $18.4M |
| Q1 2022 | 35 | $33.2M |
| Q4 2021 | 38 | $46.5M |
| Q3 2021 | 36 | $43.7M |
| Q2 2021 | 40 | $69.3M |
| Q1 2021 | 50 | $134.0M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Protara Therapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 1,900,000 | $3.48M | 0.04% | 00.0% | Unchanged |
| Opaleye Management Inc. | 1,681,154 | $3.08M | 0.51% | −623,108−27.0% | Reduced |
| StemPoint Capital LP | 942,857 | $1.73M | 0.52% | −41,256−4.2% | Reduced |
| Woodline Partners LP | 851,567 | $1.56M | 0.01% | +751,566+751.6% | Added |
| Boxer Capital, LLC | 811,627 | $1.49M | 0.07% | 00.0% | Unchanged |
| Vanguard Group Inc | 759,612 | $1.39M | 0.00% | +332,000+77.6% | Added |
| Citadel Advisors LLC | 680,511 | $1.25M | 0.00% | +15,139+2.3% | Added |
| Velan Capital Investment Management LP | 574,000 | $1.05M | 1.14% | +94,000+19.6% | Added |
| Baker Bros. Advisors LP | 536,832 | $982.4K | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 336,740 | $616.2K | 0.00% | +186,340+123.9% | Added |
| Two Sigma Investments, LP | 185,223 | $339.0K | 0.00% | +29,450+18.9% | Added |
| Oppenheimer & Co Inc | 179,125 | $327.8K | 0.00% | +51,944+40.8% | Added |
| Geode Capital Management, LLC | 170,040 | $311.2K | 0.00% | +29,514+21.0% | Added |
| Ikarian Capital, LLC | 155,712 | $285.0K | 0.09% | −25,000−13.8% | Reduced |
| Two Sigma Advisers, LP | 151,618 | $277.5K | 0.00% | +71,100+88.3% | Added |
| BlackRock, Inc. | 116,977 | $214.1K | 0.00% | +116,977 | New |
| Marshall Wace, LLP | 77,351 | $141.6K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 49,200 | $90.0K | 0.00% | +25,000+103.3% | Added |
| LPL Financial LLC | 46,000 | $84.2K | 0.00% | +2,000+4.5% | Added |
| Truist Financial Corp | 40,000 | $73.2K | 0.00% | +20,000+100.0% | Added |
| XTX Topco Ltd | 32,682 | $59.8K | 0.00% | +32,682 | New |
| Northern Trust Corp | 28,976 | $53.0K | 0.00% | 00.0% | Unchanged |
| CIBC World Markets Inc. | 28,000 | $51.0K | 0.00% | −9,000−24.3% | Reduced |
| State Street Corp | 26,600 | $48.7K | 0.00% | 00.0% | Unchanged |
| Commonwealth Equity Services, LLC | 19,428 | $36.0K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 17,907 | $32.8K | 0.00% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 17,398 | $31.8K | 0.00% | −2,793−13.8% | Reduced |
| Millennium Management LLC | 14,402 | $26.4K | 0.00% | +14,402 | New |
| UBS Group AG | 7,418 | $13.6K | 0.00% | +7,418 | New |
| Royal Bank of Canada | 3,500 | $6.00K | 0.00% | −2,802−44.5% | Reduced |
| Tower Research Capital LLC (TRC) | 2,783 | $5.09K | 0.00% | −1,236−30.8% | Reduced |
| Semmax Financial Advisors Inc. | 1,572 | $4.06K | 0.00% | +1,572 | New |
| Bank of America Corp | 366 | $670 | 0.00% | +217+145.6% | Added |
| Advisor Group Holdings, Inc. | 100 | $183 | 0.00% | 00.0% | Unchanged |
| Simplex Trading, LLC | 373 | $0 | 0.00% | +373 | New |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −520,000−100.0% | Sold out |
| Privium Fund Management (UK) Ltd | 0 | $0 | 0.00% | −114,708−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −12,850−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −10,036−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −2,550−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| CVI Holdings, LLC | – | – | – | – | Not filed |
| BlackRock Inc. | – | – | – | – | Not filed |